Therapeutic Antibodies Market in China 2023

The therapeutic antibodies market in China is likely to register a CAGR of over 26.95% with an incremental growth of USD 42.7 billion during the forecast period 2023-2029.

Therapeutic antibodies are a type of medication that is designed to target specific proteins in the body that are involved in disease processes. They are typically made from human or animal cells that have been genetically engineered to produce antibodies that can recognize and bind to a specific target protein. Once bound to the target protein, therapeutic antibodies can either block its activity or trigger an immune response against it, depending on the specific mechanism of action. Therapeutic antibodies have been developed to treat a wide range of diseases, including cancer, autoimmune disorders, infectious diseases, and inflammatory conditions. They are often used in combination with other medications, such as chemotherapy or immunosuppressive drugs, to improve treatment outcomes and reduce side effects. The therapeutic antibodies market in China is likely to register a CAGR of over 26.95% with an incremental growth of USD 42.7 billion during the forecast period 2023-2029. This industry report offers market estimates of the China market, followed by a detailed analysis of the type. The China market data on therapeutic antibodies can be segmented by type: antibody-drug conjugate (ADC), BsAb, monospecific Ab, others.

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

The China therapeutic antibodies market is highly competitive. As of 2022, the major players in the China therapeutic antibodies market were 3SBio Inc., Bristol-Myers Squibb Company, Chengdu Kanghong Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Merck & Co., Novartis International AG, Roche Holding AG, Sinopharm Corporation Ltd. The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors. Why buy this report? ? Get a detailed picture of the China Therapeutic Antibodies Market ? Identify segments/areas to invest in over the forecast period in the China Therapeutic Antibodies Market ? Understand the competitive environment, the market’s leading players ? The market estimate for ease of analysis across scenarios in Excel format. ? Strategy consulting and research support for three months. ? Print authentication provided for the single-user license.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Table of Contents

  • Part 1. Summary
  • Part 2. Introduction
  • Study period
  • Geographical scope
  • Market segmentation
  • Part 3. Therapeutic antibodies market overview
  • Part 4. Market breakdown by type
  • Antibody-drug conjugate (ADC)
  • BsAb
  • Monospecific Ab
  • Others
  • Part 5. Key companies
  • 3SBio Inc.
  • Bristol-Myers Squibb Company
  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co.
  • Novartis International AG
  • Roche Holding AG
  • Sinopharm Corporation Ltd.
  • Part 6. Methodology


Therapeutic Antibodies Market in China 2023

Contact usWe are friendly and approachable, give us a call.